Target

JAK3

4 products, 9 indications

Indications

myelofibrosis (1 products)

polycythemia vera (1 products)

steroid-refractory acute graft-versus-host disease (1 products)

corticosteroid-refractory chronic graft-versus-host disease (1 products)

mild to moderate atopic dermatitis (1 products)

Nonsegmental Vitiligo (1 products)

glioblastoma (1 products)

Ovarian cancer, primary peritoneal cancer, fallopian tube cancer (1 products)

alopecia areata (1 products)

2 drugs

2 abstracts

Abstract

Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF).

Org: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Leukemia, MD Anderson Cancer Center, Houston, TX,

Abstract

Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report.

Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Cleveland Clinic Brunswick Urgent Care, Cleveland Clinic Foundation, Cleveland Clinic Taussig Cancer Instititute,

Drug

Ruxolitinib

Drug

LITFULO